Latest news with #SethBlackley
Yahoo
7 hours ago
- Business
- Yahoo
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA
Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON, June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M. John Johnson, Evolent's Chief Financial Officer, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thirds of the quarter. We remain confident in meeting or beating the expectations we set for the 2nd quarter and full year. If these trends continue through June, we would anticipate being in the top half of our range for Q2 Adjusted EBITDA." The company also announced it signed a Commitment Letter with Ares Management Credit funds, securing the option to borrow additional non-dilutive capital, if needed, to address its 2025 Convertible Notes while leaving incremental working capital on its balance sheet to support Evolent's accelerating organic growth pipeline. Seth Blackley, Evolent's Chief Executive Officer, noted, "A recent acceleration in our business development activities has led us to significantly increase our forecast for new revenue bookings going into 2026. This option for incremental, non-dilutive capital availability ensures we can execute on any working capital needs associated with that higher growth forecast." About Evolent Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting Contacts:investorrelations@ Forward-Looking Statements Certain statements made in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: "believe," "anticipate," "expect," "estimate," "aim," "predict," "potential," "continue," "plan," "project," "will," "should," "shall," "may," "might" and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to the company's full year and second quarter 2025 guidance, availability of borrowings under the commitment letter, sufficiency of capital for the company's working capital needs associated with a higher growth forecast, and the company's forecast for new revenue bookings going into 2026. The company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. By their nature, forward-looking statements are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those projected. These risks and uncertainties are discussed under the headings "Forward-Looking Statements - Cautionary Language," and "Risk Factors," in the company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the U.S. Securities and Exchange Commission (the "SEC"), and in the company's other filings with the SEC, including its Quarterly Report on Form 10-Q for the period ended March 31, 2025, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. Except for any ongoing obligation to disclose material information as required by the United States federal securities laws, the company does not have any intention or obligation to publicly update or revise any forward-looking statements after issuing this release, whether to reflect any future events or circumstances or otherwise Non-GAAP Measures The company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include loss on repayment/extinguishment of debt; gain (loss) from equity method investees, loss on option exercise, change in fair value of contingent consideration, change in tax receivable agreement liability, other income (expense), gain (loss) on disposal of non-strategic assets, right-of-use asset impairments, losses on lease terminations, repositioning costs, stock-based compensation expense, severance costs, dividends and accretion on Series A Preferred Stock and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgements, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant. View original content to download multimedia: SOURCE Evolent Health, Inc.
Yahoo
10-06-2025
- Business
- Yahoo
EVH Q1 Earnings Call: Oncology Navigation Launch and AI Automation Drive Strategic Focus
Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results exceeding the market's revenue expectations , but sales fell by 24.4% year on year to $483.6 million. Revenue guidance for the full year exceeded analysts' estimates, but next quarter's guidance of $455 million was less impressive, coming in 9.4% below expectations. Its non-GAAP profit of $0.06 per share was 33% below analysts' consensus estimates. Is now the time to buy EVH? Find out in our full research report (it's free). Revenue: $483.6 million vs analyst estimates of $461.2 million (24.4% year-on-year decline, 4.9% beat) Adjusted EPS: $0.06 vs analyst expectations of $0.10 (33% miss) Adjusted EBITDA: $36.86 million vs analyst estimates of $33.82 million (7.6% margin, 9% beat) The company reconfirmed its revenue guidance for the full year of $2.09 billion at the midpoint EBITDA guidance for the full year is $150 million at the midpoint, in line with analyst expectations Operating Margin: -0.3%, up from -2.1% in the same quarter last year Sales Volumes rose 6.6% year on year (19.5% in the same quarter last year) Market Capitalization: $982.5 million Evolent Health's first quarter performance was shaped by evolving customer demand for specialty condition management and continued expansion within its core product areas. CEO Seth Blackley highlighted the company's addition of five new revenue agreements across oncology, musculoskeletal, and surgical management lines, attributing these wins to Evolent Health's ability to address complex clinical needs for both new and existing clients. The company also completed contractual transitions impacting its revenue mix, most notably shifting certain Performance Suite contracts from gross to net accounting, while maintaining strong renewal rates with major health plan partners. Management called out initial traction for its AuthIntel AI automation solution, noting early improvements in clinician satisfaction and process efficiency. Despite these operational gains, leadership acknowledged the quarter's underlying margin improvement was not fully realized in reported figures, as claims trends and contract transitions continued to influence financial results. Looking forward, management emphasized a focus on scaling its new oncology navigation platform and further integrating automation to drive both growth and profitability. Seth Blackley stated, 'Our oncology navigation solution combines internally developed protocols, digital tools, and newly acquired navigation assets to deliver a more comprehensive care management experience.' The company expects these innovations to expand its addressable market and enhance value delivered to health plan clients, particularly as payers seek solutions to manage rising specialty care costs. CFO John Johnson noted that Evolent Health is closely monitoring medical cost trends, particularly in oncology, but will not update its guidance until additional claims data provides a clearer trend. The leadership team also highlighted ongoing efforts to optimize contract structures and automate claim reviews, aiming to accelerate operational efficiencies and improve member outcomes in the coming quarters. Management attributed the quarter's outcomes to contract transitions, new business wins in specialty management, and the initial rollout of AI-driven automation, while also launching a major oncology navigation platform. Contract transitions impacted revenue: The shift of certain Performance Suite contracts from gross to net accounting influenced reported revenue, with CFO John Johnson explaining these changes were anticipated and EBITDA-neutral, but temporarily inflated topline results. Specialty management platform growth: Five new agreements were signed, including first-time contracts for surgical management with national and regional health plans, and geographic expansion of oncology and musculoskeletal solutions with existing clients, resulting in approximately 1 million additional covered lives. Oncology navigation launch: Evolent Health officially launched its integrated oncology navigation solution, combining in-house protocols, newly acquired navigation assets from Oncology Care Partners, and the Careology digital app. Management reported early client deployments and indicated this offering could increase savings opportunities by 10-20% compared to prior solutions. AI and automation adoption: The company deployed its AuthIntel AI tool to streamline clinical review processes, delivering faster patient resolutions and improved clinician satisfaction. While still early, management sees significant long-term opportunity for automation to boost productivity and reduce manual workload. Performance Suite margin maturation: Margin improvement initiatives are underway, with management noting favorable leading indicators in oncology cost trends, though full benefit realization awaits more complete claims data. John Johnson emphasized that annual contract repricing and corridor structures are helping maintain margin stability across evolving payer mixes. Evolent Health's outlook is driven by scaling its oncology navigation solution, increasing automation, and maintaining disciplined contract management to navigate evolving policy and industry trends. Oncology navigation platform scaling: Management expects broader adoption of the integrated oncology navigation solution to increase the value delivered to clients, citing early evidence of improved patient engagement and potential for expanded savings, especially as the offering addresses both clinical and non-clinical aspects of cancer care. AI-driven productivity gains: Leadership anticipates that further automation of claims reviews and clinical workflows will reduce processing times and operational costs through 2025 and beyond, while reiterating that AI is used only to support approvals and not to restrict access to care. Policy and payer dynamics: The company is monitoring potential policy changes in Medicare and Medicaid but expects limited near-term impact due to contract structures allowing for rate adjustments if drug costs rise. Diversification across payer types and continued annual repricing cycles are expected to help buffer against macro and regulatory headwinds. In the coming quarters, the StockStory team will watch (1) the pace and client uptake of the new oncology navigation platform, (2) evidence of sustained margin improvement from expanding automation and contract repricing, and (3) any shifts in medical cost trends—particularly in oncology and cardiology—that could influence guidance updates. Additional focus will be on the company's execution of planned Performance Suite go-lives and integration of newly acquired assets. Evolent Health currently trades at a forward P/E ratio of 15.3×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
Evolent Health (NYSE:EVH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations
Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results beating Wall Street's revenue expectations , but sales fell by 24.4% year on year to $483.6 million. Revenue guidance for the full year exceeded analysts' estimates, but next quarter's guidance of $455 million was less impressive, coming in 9.4% below expectations. Its non-GAAP profit of $0.06 per share was 37.7% below analysts' consensus estimates. Is now the time to buy Evolent Health? Find out in our full research report. Revenue: $483.6 million vs analyst estimates of $461.2 million (24.4% year-on-year decline, 4.9% beat) Adjusted EPS: $0.06 vs analyst expectations of $0.10 (37.7% miss) Adjusted EBITDA: $36.86 million vs analyst estimates of $33.82 million (7.6% margin, 9% beat) The company reconfirmed its revenue guidance for the full year of $2.09 billion at the midpoint EBITDA guidance for the full year is $150 million at the midpoint, in line with analyst expectations Operating Margin: -0.3%, up from -2.1% in the same quarter last year Free Cash Flow was -$4.03 million compared to -$438,000 in the same quarter last year Sales Volumes fell 99.9% year on year (19.5% in the same quarter last year) Market Capitalization: $1.21 billion Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA. We continue to see a very strong selling environment and we achieved significant organic growth with five new revenue agreements announced today. Operationally, we continue scaling our innovative oncology condition management solution to help Evolent further impact specialty care member experience, costs and outcomes. Performance Suite margins, including leading indicators on utilization, and AI-based automation initiatives, like Auth Intel, are both currently tracking favorably. From an innovation perspective we remain focused on improving member and provider experience in specialty care, while continuing to manage affordability for the system – a combination we believe Evolent is uniquely positioned to deliver. In the time ahead we'll remain disciplined in capital allocation, prioritizing cash generation and debt paydown. I am proud of our recent progress and I believe that our strong pipeline, low market penetration, innovative product stack and highly engaged team of 4,500 professionals, positions Evolent to deliver sustained value to our shareholders, partners and members in the short and long term." Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions. A company's long-term sales performance can indicate its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Evolent Health grew its sales at an excellent 22.5% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Evolent Health's annualized revenue growth of 27.2% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. We can dig further into the company's revenue dynamics by analyzing its number of average lives on platform, which reached 77,079 in the latest quarter. Over the last two years, Evolent Health's average lives on platform averaged 134% year-on-year growth. Because this number is better than its revenue growth, we can see the company's average selling price decreased. This quarter, Evolent Health's revenue fell by 24.4% year on year to $483.6 million but beat Wall Street's estimates by 4.9%. Company management is currently guiding for a 29.7% year-on-year decline in sales next quarter. Looking further ahead, sell-side analysts expect revenue to decline by 8.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and implies its products and services will face some demand challenges. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. Although Evolent Health broke even this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 5% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. On the plus side, Evolent Health's operating margin rose by 26.9 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its past improvements as the company's margin was relatively unchanged on two-year basis. Evolent Health's operating margin was negative 0.3% this quarter. The company's consistent lack of profits raise a flag. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Evolent Health's full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it's at a critical moment in its life. In Q1, Evolent Health reported EPS at $0.06, down from $0.34 in the same quarter last year. This print missed analysts' estimates, but we care more about long-term EPS growth than short-term movements. Over the next 12 months, Wall Street expects Evolent Health's full-year EPS of $0.38 to grow 46.3%. We enjoyed seeing Evolent Health beat analysts' revenue expectations this quarter. We were also glad its full-year revenue guidance slightly exceeded Wall Street's estimates. On the other hand, its revenue guidance for next quarter missed significantly and its EPS fell short of Wall Street's estimates. Overall, this was a mixed quarter. The stock remained flat at $10.72 immediately following the results. The latest quarter from Evolent Health's wasn't that good. One earnings report doesn't define a company's quality, though, so let's explore whether the stock is a buy at the current price. When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
Yahoo
29-04-2025
- Business
- Yahoo
Winners And Losers Of Q4: Evolent Health (NYSE:EVH) Vs The Rest Of The Healthcare Technology for Providers Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let's take a look at how Evolent Health (NYSE:EVH) and the rest of the healthcare technology for providers stocks fared in Q4. The healthcare technology industry focuses on delivering software, data analytics, and workflow solutions to hospitals, clinics, and other care facilities. These companies enable providers to streamline operations, optimize patient outcomes, and transition to value-based care models. They boast subscription-based revenues or long-term contracts, providing financial stability and growth potential. However, they face challenges such as lengthy sales cycles, significant upfront investment in technology development, and reliance on providers' adoption of new tools, which can be hindered by budget constraints or resistance to change. Over the next few years, the sector is poised for growth as providers increasingly prioritize digital transformation and efficiency in response to rising healthcare costs and patient demand for seamless care. Tailwinds include the growing adoption of AI-driven tools for patient engagement and operational improvements, government incentives for digitization, and the expansion of telehealth and remote patient monitoring. However, headwinds such as tightening hospital budgets, cybersecurity threats, and the fragmented nature of healthcare systems could slow adoption. The 6 healthcare technology for providers stocks we track reported a slower Q4. As a group, revenues beat analysts' consensus estimates by 3.1% while next quarter's revenue guidance was 0.7% below. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 11% since the latest earnings results. Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions. Evolent Health reported revenues of $646.5 million, up 16.3% year on year. This print fell short of analysts' expectations by 0.7%. Overall, it was a softer quarter for the company with a significant miss of analysts' EPS estimates and EBITDA guidance for next quarter missing analysts' expectations significantly. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent delivered fourth quarter and 2024 full-year results within the outlook range we provided in November, despite continued elevated oncology costs during the quarter. We also ended the year with 100% retention across our top customers which together represent over 90% of our 2024 revenue. Looking ahead, the recent changes we made in certain of our Performance Suite contracts as well as our assumptions for medical cost inflation make us feel confident in our financial outlook. Finally, we believe Evolent remains an incredibly unique asset; We have a strong team, a product that our customers value and a clinical approach that both manages healthcare affordability while also enabling the kind of care we would want for our family members." Evolent Health delivered the weakest performance against analyst estimates and weakest full-year guidance update of the whole group. Unsurprisingly, the stock is down 16.1% since reporting and currently trades at $9. Read our full report on Evolent Health here, it's free. Founded in 2005 to streamline the traditionally paper-heavy patient check-in process, Phreesia (NYSE:PHR) provides software solutions that automate patient intake, registration, and payment processes for healthcare organizations while improving patient engagement in their care. Phreesia reported revenues of $109.7 million, up 15.4% year on year, outperforming analysts' expectations by 0.7%. The business had a strong quarter with an impressive beat of analysts' EPS estimates and full-year EBITDA guidance topping analysts' expectations. The market seems content with the results as the stock is up 2.6% since reporting. It currently trades at $24.49. Is now the time to buy Phreesia? Access our full analysis of the earnings results here, it's free. Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency. Omnicell reported revenues of $306.9 million, up 18.6% year on year, exceeding analysts' expectations by 2.2%. Still, it was a slower quarter as it posted EBITDA guidance for next quarter missing analysts' expectations and a miss of analysts' full-year EPS guidance estimates. As expected, the stock is down 29.3% since the results and currently trades at $31.39. Read our full analysis of Omnicell's results here. Operating one of the largest healthcare group purchasing organizations in the United States with over 4,350 hospital members, Premier (NASDAQ:PINC) is a technology-driven healthcare improvement company that helps hospitals, health systems, and other providers reduce costs and improve clinical outcomes. Premier reported revenues of $240.3 million, down 14.2% year on year. This number met analysts' expectations. Aside from that, it was a slower quarter as it recorded a significant miss of analysts' EPS estimates and full-year revenue guidance missing analysts' expectations. Premier had the slowest revenue growth among its peers. The stock is down 7.1% since reporting and currently trades at $20.82. Read our full, actionable report on Premier here, it's free. Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ:ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models. Astrana Health reported revenues of $665.2 million, up 88.4% year on year. This result beat analysts' expectations by 6.9%. Taking a step back, it was a mixed quarter as it also produced full-year revenue guidance beating analysts' expectations. Astrana Health pulled off the fastest revenue growth and highest full-year guidance raise among its peers. The stock is down 12.1% since reporting and currently trades at $30.50. Read our full, actionable report on Astrana Health here, it's free. In response to the Fed's rate hikes in 2022 and 2023, inflation has been gradually trending down from its post-pandemic peak, trending closer to the Fed's 2% target. Despite higher borrowing costs, the economy has avoided flashing recessionary signals. This is the much-desired soft landing that many investors hoped for. The recent rate cuts (0.5% in September and 0.25% in November 2024) have bolstered the stock market, making 2024 a strong year for equities. Donald Trump's presidential win in November sparked additional market gains, sending indices to record highs in the days following his victory. However, debates continue over possible tariffs and corporate tax adjustments, raising questions about economic stability in 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
Yahoo
17-04-2025
- Business
- Yahoo
Evolent Health Insiders Placed Bullish Bets Worth US$1.35m
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Evolent Health, Inc. (NYSE:EVH), it sends a favourable message to the company's shareholders. While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether. We've discovered 1 warning sign about Evolent Health. View them for free. Over the last year, we can see that the biggest insider purchase was by Co-Founder Seth Blackley for US$498k worth of shares, at about US$9.01 per share. That implies that an insider found the current price of US$9.23 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Evolent Health insiders decided to buy shares at close to current prices. In the last twelve months Evolent Health insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! View our latest analysis for Evolent Health Evolent Health is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket. It's good to see that Evolent Health insiders have made notable investments in the company's shares. Overall, nine insiders shelled out US$1.3m for shares in the company -- and none sold. That shows some optimism about the company's future. I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. It appears that Evolent Health insiders own 1.6% of the company, worth about US$17m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders. The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Insiders likely see value in Evolent Health shares, given these transactions (along with notable insider ownership of the company). So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. You'd be interested to know, that we found 1 warning sign for Evolent Health and we suggest you have a look. Of course Evolent Health may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
